Efficacy of Permanent Iodine-125 Seed Implants and Gemcitabine Chemotherapy in Patients with Platinum-Resistant Recurrent Ovarian Carcinoma

  • Yang, Hui (School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, The Affiliated Hospital of Shandong Academy of Medical Sciences) ;
  • Liu, Yu-Hui (School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, The Affiliated Hospital of Shandong Academy of Medical Sciences) ;
  • Xu, Liang (Department of Radiology, Shandong Cancer Hospital and Institute) ;
  • Liu, Li-Heng (Department of Radiology, Shandong Cancer Hospital and Institute)
  • Published : 2014.11.06


Background: The aim of this study was to explore the efficacy and adverse reactions of CT-guided radioactive 125I-seed implantation treatment combined with chemotherapy for platinum-resistant recurrent ovarian carcinoma. Materials and Methods: From September 2010 to December 2012, 23 patients with platinum-resistant recurrent ovarian carcinoma were enrolled. All the patients refused, could not bear, or were not suitable for surgery. They all had no more than 3 lesions, which were detected and could also be measured by CT. All were clarified as single-lesion or multiple-lesion groups. A total of 41 lesions underwent implantation of from 8 to 106 125I seeds (median=43). Multi-plane implanting was adopted and 125I-seeds of (0.4-0.7)mCi were placed at intervals of (0.5-1.0) cm. After implantation treatment, all patients underwent 4 cycles of chemotherapy with gemcitabine $800mg/m^2$ (days 1, 8 and 15). Results: The outcome was evaluated with CT 3 weeks and every 3 months after implantation treatment. After 6 months, the volume of 32 out of 41 lesions (78.0%) was reduced at least 30%, within which 9 lesions completely disappeared(22.0%). Complete response was observed in 7 cases (30.4%), with a partial response in 4 cases (17.4%), 4 cases stable(17.4%)and 8 cases showing progression (34.8%). The total clinical remission rate was 47.8% (11/23). The clinical remission rate was 77.8% (7/9) in the single-lesion group and 28.6% (4/14) in the multiple-lesion group with a significant difference between the two(P=0.036). The common side effects observed were mild gastrointestinal reactions. Conclusions: 125I-seed implantation combined with chemotherapy applies an effective way in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma with the advantages of high local control rates, good short-term effects, little trauma and less side effects.


  1. Scarabelli C, Gallo A, Carbone A (2001). Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol, 83, 504-12.
  2. Schwarz SB, Thon N, Nikolajek K, et al (2012). Iodine-125 brachytherapy for brain tumours--a review. Radiat Oncol, 7, 30.
  3. Shapiro JD, Millward MJ, Rischin D, et al (1996). Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol, 63, 89-93.
  4. Sohaib A (2012). RECIST rules. Cancer Imaging, 12, 345-6.
  5. Hiss DC, Gabriels GA, Folb PI (2007). Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cells. Cancer Cell Int, 7, 5.
  6. Su A, Zhang J, Pan ZH, et al (2013). Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 1841-6.
  7. Trombetta MG, Colonias A, Makishi D, et al (2008). Tolerance of the aorta using intraoperative iodine-125 interstitial brachytherapy in cancer of the lung. Brachytherapy, 7, 50-4.
  8. Ding Z-Y, Zhou L, Liu Y-M, et al (2013). Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study. Thoracic Cancer, 4, 14-9.
  9. Hockel M, Sclenger K, Hamm H, et al (1996). Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall. Cancer, 77, 1918-33.<1918::AID-CNCR24>3.0.CO;2-1
  10. Kesarwala AH, Grover S, Rengan R (2013). Role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer. Thoracic Cancer, 4, 95-101.
  11. Liebling M, Boyd M, Rubio E, et al (2013). Airway metastasis of small cell lung carcinoma: A rare presentation. Thoracic Cancer, 4, 461-4.
  12. Lund B, Hansen OP, Theilade K, et al (1994). Phase II study of gemcitabine (2', 2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst, 86, 1530-3.
  13. Martinez-Monge R, Cambeiro M (2005). New techniques in irradiation: clinical implications of perioperative high-dose rate brachytherapy. Ann Oncol, 16, 73-8.
  14. Peng S, Yang QX, Zhang T, et al (2014). Lobaplatin-TACE combined with radioactive $^{125}I$ seed implantation for treatment of primary hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 5155-60.
  15. Nag S, DeHaan M, Scruggs G, et al (2006). Long-term followup of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys, 64, 736-44.
  16. Nam S-J, Oak C-H, Jang T-W, et al (2013). Successful treatment of a tracheal squamous cell carcinoma with a combination of cryoablation and photodynamic therapy. Thoracic Cancer, 4, 191-4.
  17. Nurwidya F, Takahashi F, Takahashi K (2012). Meeting report: Current cancer perspectives from the 9th Annual Meeting of the Japanese Society of Medical Oncology. Thoracic Cancer, 3, 94-7.
  18. Chen AP, Setser A, Anadkat MJ, et al (2012). Grading dermatologic adverse events of cancer treatments: the Common terminology criteria for adverse events version 4. 0. J Am Acad Dermatol, 67, 1025-39.
  19. Chumworathayi B (2013). Personalized cancer treatment for ovarian cancer. Asian Pac J Cancer Prev, 14, 1661-4.
  20. Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, et al (2013). Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Asian Pac J Cancer Prev, 14, 2421-7.
  21. Rogers BE, Rosenfeld ME, Khazaeli MB, et al (1997). Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med, 38, 1221-9.

Cited by

  1. Radiofrequency ablation and percutaneous permanent iodine-125 implantation as salvage therapy for giant recurrent sclerosing epithelioid fibrosarcoma of the chest wall: A case report pp.1792-1082, 2015,
  2. Permanent Iodine-125 Seed Implantation for the Treatment of Nonresectable Retroperitoneal Malignant Tumors vol.18, pp.1533-0338, 2019,